StockData
InspireMD, Inc. logo

InspireMD, Inc. (NSPR) shareholders

NSPRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/3054% below fair value
$0.65+0.05 (+8.33%)

Close on Nov 17, 2026Market cap $30.22MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
53.6%
25M of 46M shares
Institutional holders
37
7 new, 5 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
22 buys · 12 sales
Net bought $824.47K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Marshall Wace, Llp28,103,6999.99%13G (passive) amendmentSep 30, 2025
Aharon Gil
Joint filing with Rosalind Advisors, Inc. (9.90%), Salamon Steven A J (9.90%) and 1 more
10,987,1049.90%13G (passive) amendmentAug 1, 2025
Rosalind Advisors, Inc.
Joint filing with Salamon Steven A J (9.20%), Aharon Gil (9.20%) and 1 more
10,987,1049.20%13G (passive) amendmentDec 31, 2025
Salamon Steven A J
Joint filing with Rosalind Advisors, Inc. (9.40%), Aharon Gil (9.40%) and 1 more
10,987,1049.40%13G (passive) amendmentMar 31, 2025
Daniel Mack
Joint filing with Nantahala Capital Management, LLC (9.99%), Wilmot B. Harkey (9.99%)
4,819,6479.99%13G (passive) amendmentMar 31, 2026
Wilmot B. Harkey
Joint filing with Nantahala Capital Management, LLC (9.99%), Daniel Mack (9.99%)
4,255,7299.99%13G (passive) amendmentSep 30, 2025
Michael A. Lawless3,614,7318.60%13D (active)Jun 26, 2025
Aberdeen Group plc
Joint filing with abrdn Inc. (7.49%)
3,173,3647.49%13G (passive) amendmentDec 31, 2025
Orbimed Advisors LLC
Joint filing with OrbiMed Capital GP IX LLC (6.80%)
3,133,4057.40%13G (passive)Dec 31, 2025
Nantahala Capital Management, LLC
Joint filing with Wilmot B. Harkey (9.99%), Daniel Mack (9.99%)
3,037,9359.99%13G (passive) amendmentMar 31, 2025
Marvin Slosman2,556,7605.18%13D (active)Jan 22, 2026
Parkman Healthcare Partners LLC
Joint filing with Parkman Healthcare Partners Holdings LP (5.80%), Parkman Healthcare Partners Holdings GP LLC (5.80%) and 1 more
2,440,6335.80%13G (passive)Sep 30, 2025
Nantahala Capital Partners Limited Partnership2,418,0165.68%13G (passive) amendmentSep 30, 2025
Venkataraman Balaji
Joint filing with Velan Capital Master Fund LP (5.10%), Velan Capital Holdings LLC (5.10%) and 3 more
2,143,6985.10%13G (passive)Jul 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of NSPRValueChange% of portfolio
Nantahala Capital Management, LLC6,752,96814.53%$4.73M+3,376,4840.08%
Rosalind Advisors, Inc.3,905,7438.40%$2.73M–1.02%
abrdn plc3,698,3647.96%$2.59M+525,0000.00%
Orbimed Advisors LLC3,133,4056.74%$2.19M–0.04%
Parkman Healthcare Partners LLC2,416,5185.20%$1.69M–0.17%
Marshall Wace, Llp1,860,4054.00%$1.30M–0.00%
Soleus Capital Management, L.P.1,045,7082.25%$732.10K–0.03%
Pura Vida Investments, LLC450,5170.97%$315.41K–1.91%
Ingalls & Snyder LLC368,8000.79%$258.00K−10,5000.01%
Affiance Financial, LLC250,3700.54%$175.28K–0.03%
Velan Capital Investment Management LP148,1380.32%$103.71K−1,951,5140.06%
BlackRock, Inc.122,9930.26%$86.11K+42,5440.00%
Renaissance Technologies LLC112,8320.24%$78.99K+95,2230.00%
Creative Planning108,9640.23%$76.29K+89,2500.00%
Schonfeld Strategic Advisors LLC99,2750.21%$69.50KNew0.00%
Hrt Financial LP59,7540.13%$41.00KNew0.00%
XTX Topco Ltd49,0290.11%$34.33K+36,6710.00%
Centiva Capital, LP44,1230.09%$30.89K+19,3570.00%
Cambridge Investment Research Advisors, Inc.40,3320.09%$28.00KNew0.00%
Millennium Management LLC37,6770.08%$26.38K−74,7460.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20263725M53.6%7 / 115 / 54M2M
Q1 20263523M49.0%3 / 410 / 120M0M
Q4 20254523M49.8%12 / 76 / 82M2M
Q3 20254123M48.9%10 / 153 / 59M1M
Q2 20253614M30.3%9 / 90 / 81M0M
Q1 20253513M27.8%7 / 45 / 11M1M
Q4 20243013M27.3%4 / 53 / 21M1M
Q3 20242812M26.7%5 / 25 / 10M2M
Q2 20242414M30.1%1 / 33 / 44M0M
Q1 20242710M22.2%2 / 34 / 30M2M
Q4 20232812M26.8%6 / 71 / 34M0M
Q3 2023259M18.8%5 / 51 / 21M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

3 funds held NSPR in Q2 2026, 81% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of NSPRValue% of fundAs of
iShares Micro-Cap ETF114,8320.25%$80.39K0.01%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund18,2440.04%$16.80K0.00%May 31, 2026
1290 VT Micro Cap Portfolio8,1610.02%$5.71K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Marvin SlosmanCEO and President, Director3,602,8127.75%Nov 17, 2026
Michael A. LawlessChief Financial Officer807,0801.74%Nov 17, 2026
Shane Thomas GleasonChief Commercial Officer1,053,8822.27%May 21, 2026
Andrea TommasoliChief Operating Officer954,3892.05%Jan 16, 2026
Craig ShoreCFO and CAO1,112,4602.39%Jan 10, 2025
Patrick VertaEVP Clinical/Medical Affairs311,5320.67%Jan 10, 2025
Gary S. RoubinDirector988,3242.13%Nov 17, 2026
Michael BermanDirector674,5031.45%Nov 17, 2026
Paul StukaDirector1,399,2683.01%Nov 17, 2026
Scott R. WardDirector237,0960.51%May 8, 2026
Raymond W. CohenDirector92,4170.20%Jan 16, 2026
Danny L. DearenDirector102,0470.22%Jan 16, 2026
Kathryn ArnoldDirector303,0870.65%Dec 31, 2025
Thomas J. KesterDirector458,5730.99%Sep 17, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Paul Stuka
Director
Nov 13, 2026Buy+307,693$0.65$200.00K731,397
Michael A. Lawless
Chief Financial Officer
Nov 13, 2026Buy+115,385$0.65$75.00K807,080
Michael Berman
Director
Nov 13, 2026Buy+76,923$0.65$50.00K429,509
Marvin Slosman
CEO and President, Director
Nov 13, 2026Buy+46,154$0.65$30.00K3,602,812
Gary S. Roubin
Director
Nov 13, 2026Buy+153,846$0.65$100.00K988,324
Paul Stuka
Director
May 27, 2026Buy+20,000$0.88$17.60K667,871
Shane Thomas Gleason
Chief Commercial Officer
May 19, 2026Sale−22,778$1.01$23.01K1,053,882
Paul Stuka
Director
May 14, 2026Buy+5,000$1.15$5.75K647,871
Paul Stuka
Director
May 13, 2026Buy+10,000$1.16$11.60K642,871
Marvin Slosman
CEO and President, Director
May 12, 2026Buy+21,000$1.20$25.20K3,556,658
Paul Stuka
Director
May 11, 2026Buy+10,000$1.19$11.90K632,871
Paul Stuka
Director
May 11, 2026Buy+10,000$1.19$11.90K632,871
Paul Stuka
Director
May 8, 2026Buy+65,626$1.16$76.13K622,871
Paul Stuka
Director
May 8, 2026Buy+65,626$1.16$76.13K622,871
Gary S. Roubin
Director
May 7, 2026Buy+90,000$1.18$106.20K834,478
Paul Stuka
Director
May 7, 2026Buy+6,378$1.15$7.33K531,599
Scott R. Ward
Director
May 7, 2026Buy+73,255$1.15$84.24K237,096
Paul Stuka
Director
May 6, 2026Buy+1,517$1.12$1.70K525,221
Scott R. Ward
Director
May 6, 2026Buy+15,995$1.15$18.39K163,841
Shane Thomas Gleason
Chief Commercial Officer
Feb 2, 2026Sale−2,941$1.59$4.68K1,076,660
Shane Thomas Gleason
Chief Commercial Officer
Feb 2, 2026Sale−2,000$1.60$3.20K1,139,177
Shane Thomas Gleason
Chief Commercial Officer
Jan 30, 2026Sale−2,900$1.63$4.73K1,141,177
Shane Thomas Gleason
Chief Commercial Officer
Jan 29, 2026Sale−5,000$1.65$8.25K1,144,077
Shane Thomas Gleason
Chief Commercial Officer
Jan 28, 2026Sale−12,395$1.65$20.45K1,149,077
Shane Thomas Gleason
Chief Commercial Officer
Jan 27, 2026Sale−4,781$1.66$7.94K1,161,472
Shane Thomas Gleason
Chief Commercial Officer
Jan 22, 2026Sale−8,411$1.57$13.21K1,166,253
Shane Thomas Gleason
Chief Commercial Officer
Jan 21, 2026Sale−17,593$1.62$28.50K1,174,664
Shane Thomas Gleason
Chief Commercial Officer
Jan 20, 2026Sale−2,955$1.59$4.70K1,192,257
Shane Thomas Gleason
Chief Commercial Officer
Jan 16, 2026Sale−2,250$1.61$3.62K1,195,212
Shane Thomas Gleason
Chief Commercial Officer
Jan 15, 2026Sale−2,909$1.58$4.60K1,197,462
Raymond W. Cohen
Director
Jan 14, 2026Award+44,030––92,417
Scott R. Ward
Director
Jan 14, 2026Award+88,053––147,846
Paul Stuka
Director
Jan 14, 2026Award+132,076––523,704
Marvin Slosman
CEO and President, Director
Jan 14, 2026Award+1,114,792––3,535,658
Michael Berman
Director
Jan 14, 2026Award+88,053––352,586
Gary S. Roubin
Director
Jan 14, 2026Award+88,053––744,478
Andrea Tommasoli
Chief Operating Officer
Jan 14, 2026Award+226,695––954,389
Michael A. Lawless
Chief Financial Officer
Jan 14, 2026Award+226,695––691,695
Shane Thomas Gleason
Chief Commercial Officer
Jan 14, 2026Award+453,390––1,200,371
Danny L. Dearen
Director
Jan 14, 2026Award+44,030––102,047
Kathryn Arnold
Director
Dec 30, 2025Award+55,556––303,087
Paul Stuka
Director
Dec 9, 2025Buy+2,710$1.81$4.91K391,628
Paul Stuka
Director
Dec 9, 2025Buy+5,073$1.81$9.18K391,628
Paul Stuka
Director
Dec 5, 2025Buy+5,073$1.86$9.44K388,918
Paul Stuka
Director
Dec 4, 2025Buy+10,130$1.85$18.74K383,845
Paul Stuka
Director
Nov 12, 2025Buy+13,431$1.62$21.76K373,715
Gary S. Roubin
Director
Oct 7, 2025Award+48,000––656,425
Thomas J. Kester
Director
Sep 15, 2025Award+37,815––458,573
Marvin Slosman
CEO and President, Director
Jul 30, 2025Buy+10,330$2.42$25.00K2,420,866
Paul Stuka
Director
Jul 30, 2025Buy+20,661$2.42$50.00K444,195
Thomas J. Kester
Director
Jul 30, 2025Buy+30,991$2.42$75.00K420,758
Gary S. Roubin
Director
Jul 30, 2025Buy+41,322$2.42$100.00K608,425
Thomas J. Kester
Director
Jul 11, 2025Option exercise+30,624$1.38$42.26K389,767
Paul Stuka
Director
Jul 1, 2025Option exercise+87,500$1.38$120.75K423,534
Michael Berman
Director
Jun 29, 2025Option exercise+61,248$1.38$84.52K244,994
Gary S. Roubin
Director
Jun 25, 2025Option exercise+30,624$1.38$42.26K567,103
Shane Thomas Gleason
Chief Commercial Officer
May 30, 2025Sale−7,186$2.51$18.04K1,079,601
Shane Thomas Gleason
Chief Commercial Officer
May 29, 2025Sale−3,760$2.51$9.44K1,086,787
Shane Thomas Gleason
Chief Commercial Officer
May 27, 2025Sale−1,572$2.51$3.95K1,090,547
Shane Thomas Gleason
Chief Commercial Officer
May 23, 2025Sale−2,482$2.51$6.23K1,092,119

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
0.79%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+210.9%
From 0M shares
Short volume, 20 days
52.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of InspireMD's stock actually held short. Settlement fails (shares not delivered on time) peaked at 9,377 shares on Sep 16, 2026 over the last 90 days.

See a number that looks wrong?